Helena Tee
YOU?
Author Swipe
View article: Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression in adults: LQD a pragmatic randomised controlled trial Open
Background Lithium and several atypical antipsychotics are the recommended first-line augmentation options for treatment-resistant depression; however, few studies have compared them directly, and none for longer than 8 weeks. Consequently…
View article: Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK
Clinical and cost-effectiveness of lithium versus quetiapine augmentation for treatment-resistant depression: a pragmatic, open-label, parallel-group, randomised controlled superiority trial in the UK Open
National Institute for Health and Care Research Health Technology Assessment programme.
View article: Peripheral inflammatory effects of different interventions for treatment-resistant depression: A systematic review
Peripheral inflammatory effects of different interventions for treatment-resistant depression: A systematic review Open
Treatment effects on inflammatory proteins are confounded by several factors: ketamine, in most studies, was co-administered with other surgical procedures, while ketamine and ECT findings are also obscured by variable post-procedure asses…
View article: Patient perspectives of lithium and quetiapine augmentation treatment in treatment-resistant depression: A qualitative assessment
Patient perspectives of lithium and quetiapine augmentation treatment in treatment-resistant depression: A qualitative assessment Open
Background: Treatment-resistant depression (TRD) has a profound cost to patients and healthcare services worldwide. Pharmacological augmentation is one therapeutic option for TRD, with lithium and quetiapine currently recommended as first-…
View article: Who wants more social contacts? A cross-sectional study of people with psychotic disorders in England
Who wants more social contacts? A cross-sectional study of people with psychotic disorders in England Open
Many people with psychosis have few social contacts which can significantly reduce quality of life. While the symptoms of psychosis are thought to contribute to social isolation, they could also lead to the perception that patients are uni…
View article: Association of Patient Treatment Preference With Dropout and Clinical Outcomes in Adult Psychosocial Mental Health Interventions
Association of Patient Treatment Preference With Dropout and Clinical Outcomes in Adult Psychosocial Mental Health Interventions Open
This is the first review, to our knowledge, examining the association of receiving a preferred psychosocial mental health treatment with both engagement and outcomes for patients with a mental health diagnosis. Patients with mental health …